Tuesday 26th April 2011 |
Text too small? |
A company working on a cure for hepatitis C has been forced to close because of South Canterbury Finance's (SCF) receivership.
Blenheim-based pharmaceutical company Biocorp owed SCF $13.6 million and was placed into receivership by SCF's receivers on February 1, The Timaru Herald reported.
Former SCF chairman Allan Hubbard, who had a 10% shareholding in Biocorp, earlier told the National Business Review it was working on a cure for hepatitis C.
It had planned to hold clinical trials in Egypt but political unrest meant they could not go ahead.
Biocorp's receivers Jeremy Morley and John Fisk said it was placed into receivership because it defaulted on repayments to SCF.
The company owned property including land, coolstore industrial buildings and various plant and equipment at the Cloudy Bay business park in Blenheim.
SCF was placed in receivership last year after it failed to find an equity partner to shore up the company and $1.6 billion was paid out under the Government guarantee scheme.
NZPA
No comments yet
Fonterra appoints permanent COO
Manawa Energy FY24 Annual Results & Webcast Details
Seeka Provides the Results of Meeting - ASM
April 19th Morning Report
PGW Guidance Update
CNU - Commerce Commission releases draft expenditure decision
Spark announces departure of Product Director
TGG - T&G appoints new Director
April 18th Morning Report
SKC - APPOINTMENT OF CHIEF EXECUTIVE OFFICER